Brief: Elicera Therapeutics Drug Candidate Gets Orphan Drug Designation In U.S.

Elicera Therapeutics AB

13/01/2025 10:16

Jan 13 (Reuters) - Elicera Therapeutics AB  ELIC.ST :
    * ELICERA THERAPEUTICS' DRUG CANDIDATE ELC-100 RECEIVES
ORPHAN
DRUG DESIGNATION IN THE U.S. FOR THE TREATMENT OF PANCREATIC
NEUROENDOCRINE TUMORS
    * FINAL DATA FROM FIRST PART OF ELC-100 STUDY EXPECTED
MID-2025

Source text:  ID:nWkrDZL51 
Further company coverage:  ELIC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))